http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2676537-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3531f16c23cb6f8ca2bb43937e799606 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-626 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2400-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-624 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2025-1088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2025-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-42 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L29-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L29-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-0045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-1027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M29-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L29-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-04 |
| filingDate | 2010-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_597d4dc5c5da45caf30a2e91e6f77a2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2491cddb5f26c869b73cf497e6c24f97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48a3143a97a372bd2d73c2eb2987b412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5826a59a7db5dd92ae935db72c383798 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9639885e147b5d66268cc7bec17c49bd |
| publicationDate | 2018-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2676537-T3 |
| titleOfInvention | Rejuvenation of the coronary artery by improving blood flow with the help of inserting nano-balls (encapsulated nanoparticles) containing therapeutic agents by means of a non-implantable tissue device and, thus, providing tissue release treat the required cell cycle |
| abstract | A medical drug delivery device for treating a medical condition associated with a body lumen, wherein the body lumen comprises a plurality of layers, wherein the insertable medical drug delivery device comprises: a balloon catheter; and an inflatable balloon positioned in the balloon catheter, in which the inflatable balloon has a hydrophilic surface, in which at least a part of the hydrophilic surface is covered with a plurality of nanocarriers, in which a nanocarrier of the plurality of nanocarriers comprises a drug enveloped by an encapsulation medium, in which a surface of the nanocarrier is devoid of the drug, and in which the encapsulation medium comprises a phospholipid. where the plurality of nanocarriers has a single average diameter, where the single average diameter ranges from 10nm to 1000nm. wherein the plurality of nanocarriers comprises a first set of nanocarriers having a first average diameter suitable for penetrating a first layer of the plurality of body lumen layers ranging from 800nm to 1000nm, a second set of nanocarriers having a second average diameter suitable for penetrating a first layer and a second layer of the plurality of body lumen layers ranging from 300nm to 800nm, and a third set of nano-vehicles having an average diameter suitable for penetrating a first layer, a second layer and a third layer of the plurality of body lumen layers ranging from 10nm to 300nm. wherein the drug is selected from a group comprising sirolimus, paclitaxel, tacrolimus, clobetasol, dexamethasone, genistein, heparin, beta-stadiol, rapamycin, everolimus, ethylrapamycin, zotarolimus, ABT-578, Biolimus. A9, Docetaxel, Methotrexate, Azathioprine, Vincristine, Vinblastine, Fluorouracil, Doxorubicin Hydrochloride, Mitomycin, Heparin Sodium, Low Molecular Weight Heparin, Heparinoid, Hirudin, Argatroban, Forskolin, Vapiprost, Prostacyclin-Dextroxin , dipyridamole, Ilb / DIa glycoprotein, recombinant hirudin, bivalirudin, nifedipine, colchicines, lovastatin, nitroprusside, suramine, serotonin blockers, a steroid, thioprotease inhibitors, triazolopyrimidine, nitric oxide, nitric oxide donors, superiodine supermimetics of dismutase, estradiol, aspirin, angiopeptin, captopril, cilazapril, lisinopril, potassium permirolast, interferon alfa, and bioactive RGD, at least one genetically engineered flavonoid, estrogen, antibody, in which at least one flavonoid is selected from a group comprising at least one of narigenin, naringin, eriodicitol, hesperetin, speridi na (speridine), kampferol, quercetin, rutin, cyanidol, meciadonol, catechin, gallocatechin epi- gallate, taxifoline (dihydroquercetin), genistein, genistin, daidzein, biochanin, glycine, chrysin, diosmin, luetoline, apigenin, tangerine. |
| priorityDate | 2009-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 242.